Document:

Exhibit

Exhibit 10.1

August 12, 2015

Valerie Insignares
[Address Redacted]

Re:    Termination of Employment and Letter of Recommendation

Dear Valerie:

Thank you for your contributions to Darden Restaurants, Inc. (the “Company”) during your years of service to the Company.  This letter (the “Letter”) is to confirm that your last day of employment with the Company was July 24, 2015 (the “Termination Date”).

Benefits

Provided that you timely execute this Letter (no later than September 2, 2015), and do not revoke your signature during the Revocation Period (as defined below), the Company will:

		
	a)
	provide you with career transition services through Challenger, Gray & Christmas (“CG&C”), which includes individual career coaching, access to job opportunity leaders through CG&C, and access to interactive, online tools through September 14, 2016;

 
		
	b)
	reimburse you for financial and legal advisory services expenses incurred by you in connection with your employment transition up to a maximum amount of $10,000, which the Company will do within a reasonable period of time not to exceed 30 days following your submission to the Company of documentation in a form acceptable to the Company substantiating such expenses; 

		
	c)
	modify your obligations pursuant to the non-competition provisions contained in the award agreements that govern the terms and conditions of your outstanding performance stock units and non-qualified stock options so that they will only restrict your employment at casual steakhouse restaurants with an all day per person check average of $25 or lower that derive more than 30% of their food sales from the sale of steak products and, subject to the foregoing, will not restrict your employment by a multi-brand company so long as your work does not involve working with a restaurant brand of the type described in this sentence, provided that, for the avoidance of doubt, the Company will not release you from any other obligations in such award agreements, including your obligations pursuant to the non-solicitation, non-recruitment and non-disclosure provisions which shall remain in place until July 24, 2017; and

 
		
	d)
	provide you with a letter of recommendation substantially in the form attached hereto as Exhibit A. 

1

Release

You, for yourself, your spouse and your agents, successors, heirs, executors, administrators and assigns, in consideration of the benefits provided pursuant to this Letter and other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, hereby irrevocably and unconditionally forever releases and discharges the Company, its parents, divisions, subsidiaries and affiliates and its and their current and former owners, directors, officers, shareholders, insurers, benefit plans, representatives, agents and employees, and each of their predecessors, successors, and assigns (collectively, “the Releasees”), from any and all actual or potential claims or liabilities of any kind or nature, including, but not limited to, any claims arising out of or related to your employment and separation from employment with the Company and any services that you provided to the Company as an employee; any claims for salary, commissions, bonuses, other severance pay, vacation pay, allowances or other compensation, or for any benefits under the Employee Retirement Income Security Act (except for vested ERISA benefits); any claims for discrimination, harassment or retaliation of any kind or based upon any legally protected classification or activity; any claims under Title VII of the Civil Rights Acts of 1964, the Age Discrimination in Employment Act, the Older Workers Benefit Protection Act, the Americans with Disabilities Act, 42 U.S.C. §1981, 42 U.S.C. § 1983, the Family Medical Leave Act and any similar state law, the Fair Credit Reporting Act and any similar state law, the Equal Pay Act and any similar state law, including the Florida Civil Rights Act, the Florida Whistleblower Act, the Florida Minimum Wage Act, Florida Statute §448.08 (and any other claim for unpaid wages or other compensation under Florida law), as well as any amendments to any such laws; any claims for any violation of any federal or state constitutions or executive orders; any claims for wrongful or constructive discharge, violation of public policy, breach of contract or promise (oral, written, express or implied), personal injury not covered by workers’ compensation benefits, misrepresentation, negligence, fraud, estoppel, defamation, infliction of emotional distress, contribution and any other claims under any other federal, state or local law, including those not specifically listed in this Letter, that you, your heirs, executors, administrators, successors, and assigns now have, ever had or may hereafter have, whether known or unknown, suspected or unsuspected, up to and including the date you execute this Letter.

For the purpose of implementing a full and complete release and discharge of the Releasees as set forth above, you acknowledge that this release is intended to include in its effect, without limitation, all claims known or unknown that you have or may have against the Releasees which arise out of or relate to your employment, including but not limited to compensation, performance or termination of employment with the Company, except for, and notwithstanding anything in this Letter to the contrary, claims which cannot be released solely by private agreement and claims to enforce your rights under the Management Continuity Agreement between you and the Company, dated as of January 14, 2013 (the “MCA”), and to enforce your rights under your performance stock units award agreements and stock option agreements. This release also excludes any claim for workers’ compensation benefits and any rights you may have to indemnification or directors’ and officers’ liability insurance under the Company’s bylaws or certificate of incorporation, any indemnification agreement to which you are a party or beneficiary or applicable law, as a result of having served as an officer, director or employee of the Company or any of its affiliates. 

You affirm, by signing this Letter, that you have not suffered any unreported injury or illness arising from your employment with the Company, and that you have not filed, with any federal, state, or local court or agency, any actions or charges against the Releasees relating to or arising out of 

2

your employment with or separation from the Company or any services that you provided to the Company as an employee.  You further agree that while this release does not preclude you from filing a charge with the National Labor Relations Board (“NLRB”), the Equal Employment Opportunity Commission (“EEOC”) or a similar state or local agency, or from participating in any investigation or proceeding with them, you do waive your right to personally recover monies or reinstatement as a result of any complaint or charge filed against the  Company with the NLRB, EEOC or any federal, state or local court or agency, except as to any action to enforce or challenge this Letter, to recover any vested benefits under ERISA, to recover benefits under the MCA, or your performance stock units award agreements or stock option agreements, or to recover workers’ compensation benefits.

You affirm, by signing this Letter, that you are not in possession of any material information concerning the business, operations or financial condition of the Company or any of its subsidiaries or affiliates that you have not delivered or otherwise communicated to, or that you are not certain is also possessed by, one or more other executive officers of the Company.  You are permitted to keep your laptop computer and iPhone 6.  

This Letter is intended to comply with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), or an exemption or exclusion therefrom and, with respect to amounts that are subject to Section 409A of the Code, will in all respects be administered in accordance with Section 409A of the Code.  To the extent any reimbursements or in-kind benefits due to you under this Letter constitute “a deferred compensation plan” under Section 409A of the Code, any such reimbursements or in-kind benefits will be paid or provided in accordance with the requirements of Section 409A of the Code, including, without limitation, (a) in no event will reimbursements by the Company under this Letter be made later than the last day of the calendar year next following the calendar year in which the expense was incurred; (b) the amount of any reimbursement or in-kind benefits that the Company is obligated to pay or provide during a given calendar year will not affect the amount of reimbursement or in-kind benefits that the Company is obligated to pay or provide in any other calendar year; and (c) your right to have the Company pay or provide such reimbursements and in-kind benefits may not be liquidated or exchanged for any other benefit.

You acknowledge:

		
	(a)
	That you were provided twenty-one (21) full days during which to consider whether to sign this Letter. If you have signed this Letter prior to the expiration of the 21-day period, you have voluntarily elected to forego the remainder of that period.

		
	(b)
	That you have carefully read and fully understand all of the terms of this Letter.

		
	(c)
	That you understand that by signing this Letter, you are waiving your rights under the Age Discrimination in Employment Act, as amended by the Older Workers Benefit Protection Act, 29 U.S.C. § 621, et seq., and that you are not waiving any rights arising after the date that this Letter is signed.

		
	(d)
	That you have been given an opportunity to consult with anyone you choose, including an attorney, about this Letter and the release it contains.

3

		
	(e)
	That you understand fully the terms and effect of this Letter and release and know of no claim that has not been released by this Letter, and, you further acknowledge that you are not aware of, or that you have fully disclosed to the Company, any matters for which you are responsible or which has come to your attention as an employee of the Company that might give rise to, evidence, or support any claim of illegal conduct, regulatory violation, unlawful discrimination, or other cause of action against the Company.

		
	(f)
	That these terms are final and binding on you.

		
	(g)
	That you have signed this Letter and release voluntarily, and not in reliance on any representations or statements made to you by any employee or officer of the Company or any of its subsidiaries.

		
	(h)
	This Letter constitutes the sole and entire agreement of the parties with respect to the subject matter hereof.

Valerie, if this Letter correctly sets forth our agreement, please sign and date the enclosed copy where indicated and return it to me. You have 7 days from the date of your acceptance of this Letter to revoke it (“Revocation Period”); if you do not revoke it within the 7-day period, it will become effective.  Revocation must be made in writing and sent to Darden Restaurants, Inc., Attn: Danielle Kirgan, 1000 Darden Center Drive, Orlando, FL 32837.

If you have any questions, please do not hesitate to contact me or Danielle.

Sincerely,

/s/ Gene Lee        
Gene Lee
Chief Executive Officer

CC: Danielle Kirgan, SVP, Chief Human Resources Officer

 

PLEASE READ CAREFULLY.  THIS AGREEMENT INCLUDES A RELEASE OF ALL KNOWN AND UNKNOWN CLAIMS.

ACKNOWLEDGED AND AGREED

/s/ Valerie Insignares                    9/2/15
Valerie Insignares                                        Date

4

EXHIBIT A

Letter of Recommendation

5

August 12, 2015

To Whom It May Concern,
Valerie Insignares had a successful career with Darden, driven by a sustained track record of business results.   She is a high energy and focused leader, consistently demonstrating her commitment and passion for the industry and her work.
Most recently, Val served as President of LongHorn Steakhouse, from January 2013 through July 2015, as well as a member of Darden’s Senior Leadership Team.   Under her leadership, Longhorn’s same restaurant sales performance consistently outpaced the industry.  LongHorn was also recognized by Industry Benchmark People Report for Best Practices in 2012 and 2013 due to top decile operations leadership retention and diversity.   
Previously, Valerie served as Chief Restaurant Operations Officer (CROO) for Darden from March 2011 to January 2013.  She was charged with leading strategic Operations initiatives across the enterprise with the goal of accelerating profitable sales growth and building an even stronger bench of future Operations leaders.  Prior to becoming CROO, she served as Executive Vice President of Olive Garden for seven years, where she led the opening of nearly 200 value-creating restaurants, while maintaining operational excellence at existing restaurants.  
Valerie began her career at Darden in the supply chain function as Director of Food and Smallwares Commodities Purchasing and held positions of increasing responsibility, including serving as Vice President of Supply Management and Diversity.   
Throughout her career Valerie has been a champion for diversity and leadership development.  She has been recognized internally by Darden, as well as by Women’s Foodservice Forum and Hispanic Business Magazine for her contributions.
I recommend Valerie for your consideration and wish her well as she embarks on the next chapter of her career.

Sincerely,
 

Gene Lee
Chief Executive Officer

6Science to Consumers, Inc.: Exhibit 10.1 - Filed by newsfilecorp.com

EXCLUSIVE LICENSE AGREEMENT 

This Agreement (the “Agreement”) is made this 16th
day of December, by and between Science To Consumers, Inc., a Nevada Corporation
with its principal place of business at Faraday 31, Leipzig, Germany (“S2C”),
and Biomatrix Inc., a Arizona corporation with its principal place of business
at PMB 1319, 2675 W Hwy 89A Sedona, AZ 86336 (“Biomatrix”). 

RECITALS 

	A. 	
      S2C has significant experience and expertise in the field
      of Direct To Consumer Sales, Marketing and distribution of Consumer Health
      Care Products.

	 	 
	B. 	
      Biomatrix owns or has the exclusive right to market and
      sell certain consumer Products, as more fully described in Exhibit A
      annexed hereto and made a part hereof (the “Products”).

	 	 
	C. 	
      Biomatrix desires that the Products be offered for sale
      by way of one or more Direct to Consumer channels and S2C desires to
      produce DR Advertisements and other marketing and sales distribution
      materials for, and sell, the Products, all on the terms and conditions set
      forth below.

	 	 
	D. 	
      S2C has the right to market and sell the products in
      other markets and other sales channels in The People’s Republic of China
      and Europe.

NOW, THEREFORE, in consideration of the agreements contained
herein and for other good and valuable consideration, the receipt and
sufficiency of which are acknowledged by the parties, the parties hereby agree
as follows:

1.     S2C’s
Obligations 

(a)          S2C
shall create Advertisements for the Products, in consultation with Biomatrix,
which shall initially consist of DR print (“DR Print”) advertisements, and shall
thereafter include DR TV commercials (“DRTV”) and other forms of DR
Advertisements following rollout of S2C’s DR Print campaign for the Initial
Products. The DRTV commercials may be of any length determined by S2C in its
sole discretion.

(b)          S2C
shall manage all creative, testing, media buying, telemarketing, fulfillment and
credit card processing relating to the sale of Products through DR
Advertisements. S2C will meaningfully consult with Biomatrix regarding
appropriate publicity and home shopping opportunities for the Products. If S2C
believes it necessary, the parties will work together to adjust packaging of the
Products. 

(c)          S2C
may, but shall not be obligated to, integrate online retail sale of the Products
into its overall web strategy, including order acceptance, billing and
collection. 

2.     Biomatrix’s
Obligations 

(a)         
Biomatrix shall (1) supply finished goods inventory for the Products (“Finished
Goods”); (2) provide claims substantiation with respect to each Product
(including without limitation any relevant clinical data and support for claims
in Biomatrix’s current print advertising); (3) provide assistance with securing
testimonials and cooperation from experts; and (4) arranging for reasonable
appearances by Burt Ensley to promote Biomatrix-derived products in DR advertising,
home shopping and other channels of distribution; (5) provide unlimited fully
cleared content required by S2C to create DR Advertisements, including without
limitation all necessary rights to use names, likenesses, etc. (“Content”); and
(6) ensure that all patent and intellectual property related to the Products and
Content are maintained in good standing, and aggressively defend them against
potential competition and infringement. S2C shall pay Biomatrix’s (i) reasonable
costs associated with clause (3) above; and (ii) standard and customary travel
and meal expenses associated with clause (4) above, provided in each case that
individual expenses in excess of $100 must be preapproved in writing by S2C.
Burt Ensley will neither be required to make home shopping appearances more than
12 times per year nor more than twice per month. Until shipment of the Products,
all inventory shall be owned by Biomatrix; thereafter it shall be owned by S2C,
subject to returns in accordance with Section 10 below. 

(b)          At no
additional cost to S2C, Biomatrix shall: 

Furnish to S2C fully cleared and pre-approved clips (video and
audio), marketing materials, use of precedent website content and images,
photographs and samples of the Products for use in the DR Advertisements (the
“Biomatrix Cleared Materials”) and notify S2C in writing of any restrictions or
limitations relating to the advertising, distribution and sale thereof; and 

(c)          All
Products shall be manufactured in accordance with good manufacturing practices,
applicable health, safety and labour standards, pursuant to all requisite
government approvals, and shall be fit for the purpose for which they are being
created. 

3.     Orders;
Pricing 

(a)         
Orders; Fulfillment. During the Term (as defined in Section 8 below), S2C
shall place orders for Products with Biomatrix on a standard purchase order that
shall solely state the quantity of Products desired, the purchase price
therefore, the delivery dates requested, and the shipment address. Biomatrix
shall respond in writing to all purchase orders that may be submitted by S2C to
Biomatrix confirming such order within five business days. Biomatrix agrees to
accept any order placed by S2C on such standard purchase order and in accordance
with the terms of this Agreement. All orders shall be shipped DDP to such
address or addresses as may be specified by S2C in the applicable purchase
order. Shipping is FOB Sedona, Arizona. 

2

(b)         
Purchase Price.

	 	i. 	
      The initial purchase price for each Product is set forth
      on a separate Agreement and will be finalized simultaneously with the
      signing of this Agreement. The purchase prices thereafter for each Product
      shall be equal to costs for such Product mutually agreed upon by the
      parties (“Costs”). Costs will be set in U.S. Dollars and will be no less
      favorable than the Costs charged by Biomatrix or its suppliers to any
      third party purchaser for similar or substantially similar
  products.

	 	 	 
	 	ii. 	
      Biomatrix shall invoice S2C for the Products purchased by
      and delivered to S2C or its designees, and S2C will pay 1⁄2 the invoice
      amount upon receipt by Biomatrix of the Purchase Order, and, within 30
      days after the date any purchase order product is shipped, pay Biomatrix
      the remaining 1⁄2 of the invoice amount for the Products so invoiced;
      provided, however, that any returns by S2C to Biomatrix in accordance with
      Section 12 hereof shall be offset from the purchase price payable in
      respect of any purchase order and invoice in respect
  thereof.

(c)         
Pricing. 

The parties anticipate that the Initial Products will be
marketed in a three SKU sales unit consisting of a one-month supply of a
DermaLastyl-based system (e.g., (x) 1-oz. jar of DermaLastyl-B, (y) 1-month
supply of DermaLastyl-E, and (z) DermaLastyl Bx Pro Fromula 1.7 Oz) for the
three SKUs (collectively, a “Sales Unit”). S2C intends to test multiple price
points and offers with respect to the Products, and does not presently know the
retail price at which it will end up selling the Sales Unit. S2C also may, but
shall not be obligated to, explore trials, sampling and lead generation
campaigns in an effort to minimize customer acquisition cost and maximize
customer lifetime value. 

4.     Production &
Test Marketing 

(a)         
Commencing on the date of this Agreement S2C will produce and begin testing DR
Advertisements for the Initial Products for a period not to exceed 365 days (the
“Testing Period”). During the Testing Period, S2C will bear all of the costs of
the test DR advertising 

(b)          S2C
will proceed with the Roll-out if it achieves positive results from its test DR
advertising during the Testing Period. At the end of the Testing Period, S2C
will assume financial and managerial responsibility for public relations in
connection with the Products. 

(c)          If
S2C fails to roll out a DR advertising campaign with respect to the Initial
Products by the end of the Testing Period, Biomatrix shall have the right to
terminate this Agreement upon 30 days’ prior written notice with no further
liability to S2C, provided, however, that any delay resulting from a failure on
the part of Biomatrix to timely furnish all materials pursuant to Sections
2(a)(1), 2(a)(2) and (5) shall not trigger Biomatrix’s rights under this Section
4(c).

(d)         
Subsequent to successful testing, S2C and Biomatrix may work together to modify
packaging of the Products by mutual agreement.

(e)          S2C
shall determine in its sole discretion whether to market the Products
individually or in any combination configuration (including continuity,
boxed-set, multi-pay and single-unit), provided that the price of each
individual SKU for a Product marketed in this manner is equal to the highest
prevailing retail price for such Product and reflects no
discount, as indicated by the current product price chart reflected on the
attached Exhibit B (subject to future price reductions by Biomatrix). 

3

5.     Exclusive
Rights.

(a)         
During the Term, S2C shall have exclusive rights (the “Exclusive Rights”) in
the People’s Republic of China and Europe to all Products in the following
channels: (i) DR television, (ii) home shopping, (iii) DR print, (iv) catalog,
(v) Direct Mail, (vi) DR radio, (vii) outbound telemarketing; (viii) online
(including eCommerce, lead generation and direct marketing) and (ix) retail.

(b)          In
consideration for the Exclusive Licensing Rights for the Territories of the
People's Republic of China and Europe, Biomatrix agrees to accept 2,000,000
restricted common shares (the “Consideration Shares”) in the capital
stock of S2C in exchange for all the issued and outstanding shares (being 1,000
common shares, the “Subsidiary Shares”) of Biomatrix Inc., an Arizona
Corporation with it's address at PMB 1319, 2675 W. Hwy 89A, Sedona, Arizona
86336 (“Biomatrix Arizona”) . Biomatrix Arizona has been assigned the
exclusive licensing rights by Protein Genomics for the territories of the
People's Republic of China and Europe pursuant to the Assignment Agreement dated
October 13, 2015 and which is attached hereto and incorporated into this
Agreement as Exhibit “B”.

(c)         
Biomatrix acknowledge and agrees that the Consideration Shares are being issued
pursuant to an exemption from the prospectus and registration requirements of
the Securities Act of 1933, as amended (the “Securities Act”). As
required by applicable securities law, Biomatrix agree to abide by all
applicable resale restrictions and hold periods imposed by all applicable
securities legislation. All certificates representing the Consideration Shares
issued on Closing will be endorsed with the following legend pursuant to the
Securities Act in order to reflect the fact that the Consideration Shares will
be issued to Biomatrix pursuant to an exemption from the registration
requirements of the Securities Act:  

"NONE OF THE SECURITIES REPRESENTED HEREBY HAVE BEEN REGISTERED
UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "1933 ACT"), OR
ANY U.S. STATE SECURITIES LAWS, AND, UNLESS SO REGISTERED, MAY NOT BE OFFERED OR
SOLD, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES (AS DEFINED HEREIN) OR TO
U.S. PERSONS EXCEPT IN ACCORDANCE WITH THE PROVISIONS OF REGULATION S UNDER THE
1933 ACT, PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE 1933 ACT, OR
PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE
REGISTRATION REQUIREMENTS OF THE 1933 ACT AND IN EACH CASE ONLY IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS. IN ADDITION, HEDGING TRANSACTIONS
INVOLVING THE SECURITIES MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE 1933
ACT. "UNITED STATES" AND "U.S. PERSON" ARE AS DEFINED BY REGULATION S UNDER THE
1933 ACT." 

(d)         
Biomatrix acknowledges that the Consideration Shares issued pursuant to the
terms and conditions set forth in this Agreement will have such hold periods as
are required under applicable securities laws and as a result may not be sold,
transferred or otherwise disposed, except pursuant to an effective registration
statement under the Securities Act, or pursuant to an exemption from, or in a
transaction not subject to, the registration requirements of the Securities Act
and in each case only in accordance with all applicable securities laws. 

4

(e)        
 Biomatrix and Biomatrix Arizona acknowledge that the acquisition of the
Subsidiary Shares by S2C shall require S2C to consolidate Biomatrix Arizona into
its financial statements and disclosure as required by U.S. securities law.
Accordingly, Biomatrix and Biomatrix Arizona agree that the closing of this
Agreement shall be subject to the delivery by Biomatrix Arizona of an audited
balance sheet of Biomatrix Arizona dated as of the most recent fiscal year end
of Biomatrix Arizona, together with related statements of income, cash flows,
and changes in shareholder’s equity for the most recent fiscal year end of
Biomatrix Arizona and the unaudited balance sheet of Biomatrix Arizona dated as
of the most recently completed fiscal quarter, together with related statements
of income, cash flows, and changes in shareholder’s equity for the interim
period ended on such date, as such other financial information as reasonably
required by S2C, its advisors, or its auditor (collectively, the “Biomatrix
Arizona Financial Statements”). Upon execution of this Agreement Biomatrix
and Biomatrix Arizona shall cooperate fully with S2C’s representatives and
auditor to facilitate the preparation of the Biomatrix Arizona Financial
Statements and such other information as may be reasonably required to fulfill
S2C’s public reporting obligations. The costs associated for the audited
financial statements will be reimbursed by S2C to Biomatrix Arizona on the
completion of the audited financial statements of Biomatrix Arizona. 

6.     Term.

The initial term of this Agreement (as such term may be renewed
pursuant to this Section 6, the “Term”) shall commence on the date of
this Agreement and shall continue for a period of 5 (5) years, provided that S2C
sells $250,000 of product in the first year and $500,000 in the Second year. The
initial Term and any renewal Term shall automatically be renewed for additional
5 (5) year periods in the event that S2C sells at least $500,000 of Products per
annum (excluding the first year) under the terms of this Agreement.

5

7.    
Ownership 

(a)          S2C
shall own the copyright in the DR Advertisements and all other materials created
by it or on its behalf in relation to this Agreement.

(b)         
  Biomatrix shall own any materials contained in the Products supplied to S2C by
  Biomatrix and nothing in this Agreement shall confer in S2C any right of
  ownership in such materials. Biomatrix grants to S2C a exclusive, non-assignable
  (except to affiliated entities), nontransferable, royalty-free license, in The
  People’s Republic of China and Europe and for the Term, to the Products for use
by S2C in creating the DR advertising in accordance with this Agreement. 

(c)         
  Biomatrix’s trademarks, service marks, trade or company names, product and
  service identifications, artwork and other symbols and devices associated with
  the Products, whether registered or unregistered(collectively the “Biomatrix’s
  Marks”) are and shall remain Biomatrix’s property. Biomatrix grants to S2C an
  exclusive, non-assignable, non-transferable, royalty-free license, in the
  People’s Republic of China and Europe and for the Term, to Biomatrix’s Marks for
  use by (except to affiliated entities) S2C solely in accordance with this
Agreement.

(d)          S2C’s
  trademarks, service markets, trade or company names, product and service
  identifications, artwork and other symbols and devices associated with the
  Products (“S2C’s Marks”) are and shall remain S2C’s property.

8.    
Returns. Biomatrix shall accept from S2C returns of
units of Products and will credit S2C for 100% of the purchase price paid by S2C
to Biomatrix for those units. 

9.    
Insurance. Each party shall obtain and maintain, at its
own expense, errors and omissions insurance covering the Products furnished by
Biomatrix to S2C hereunder, and the DR Advertisements and other advertising in
respect thereof, from a recognized and qualified insurance company in the amount
of at least One Million Dollars ($1,000,000) per occurrence and Three Million
Dollars ($3,000,000) in the aggregate. Each such policy will name the other
party as an additional insured and shall be non-cancelable by a party except
after thirty (30) days prior written notice to such other party. Each party will
furnish to the other a certificate evidencing such policy as soon as possible
after the execution of this Agreement, but in no event later than S2C’s
commencement of production of the first DRTV Commercial for a Product. 

10.     Representations
and Warranties 

(a)          S2C
represents and warrants that: 

	 	i. 	
      It has the right, authority and power to enter into and
      fully perform its obligations under this Agreement.

	 	 	 
	 	ii. 	
      To the best of S2C’s knowledge, S2C’s Marks or any use of
      them in accordance with this Agreement will not violate any law, infringe
      upon the rights of any person or entity, or other cause Biomatrix to incur
      liability to any third party, including, but not limited to, infringement
      or misappropriation of any copyright, patent, trademark, trade secret, or
      other proprietary, property or other right.

(b)         
Biomatrix represents and warrants that: 

6

	 	 i.    		
      It has the right, authority and power to enter into and
      fully perform its obligations under this Agreement. The performance of
      Biomatrix’s obligations hereunder does not and will not result in a breach
      of, default under, or conflict with any of the terms or provisions of any
      agreement or other instrument to which Biomatrix or Biomatrix Arizona is a
      party or by which either of them are bound, or any statute, order,
      judgment or other law or ruling of any competent authority;

	 	 	 	 
	 	 ii. 		
      It owns all right, title and interest in and to the
      Products defined in this Agreement, and covenants that it will own all
      right, title and interest in and to all subsequent Products incorporated
      into this Agreement, in each case free and clear of any liens or other
      encumbrances;

	 	 	 	 
	 	 iii. 		
      Biomatrix Arizona owns all right, title and interest in
      and to the Exclusive Rights set out in above Section 5, and the Assignment
      Agreement between Biomatrix Arizona and Protein Genomics dated October 13,
      2015 is in good standing as at the date hereof and no default has occurred
      therein;

	 	 	 	 
	 	 iv. 		
      Biomatrix Arizona is a corporation duly organized,
      validly existing and in good standing under the laws of the State of
      Arizona and has the requisite corporate power and authority to own, lease
      and to carry on its business as now being conducted. Biomatrix Arizona is
      duly qualified to do business and is in good standing as a corporation in
      each of the jurisdictions in which Biomatrix Arizona owns property, leases
      property, does business, or is otherwise required to do so, where the
      failure to be so qualified would have a material adverse effect on the
      business of Biomatrix Arizona taken as a whole;

	 	 	 	 
	 	 v. 		
      The entire authorized capital stock and other equity
      securities of Biomatrix Arizona consists of 1,000 common shares with par
      value of USD$0.001 per share;

	 	 	 	 
	 	 vi. 		
      Biomatrix Arizona does not have any material Liabilities,
      obligations or commitments, either direct or indirect, matured or
      unmatured, absolute, contingent or otherwise that exceed $1,000;

	 	 	 	 
	 	 vii. 		
      Biomatrix is the registered and beneficial owner of and
      will have good and marketable title to all of the Subsidiary Shares and
      will hold and maintain such securities free and clear of all liens,
      charges and encumbrances whatsoever until:(i) the Subsidiary Shares are
      duly transferred and vested in S2C in accordance with the terms of this
      Agreement, and (ii) the termination of this Agreement in accordance with
      the terms hereof, whichever is earlier.

	 	 	 	 
	 	 viii. 		
      Biomatrix is an "Accredited Investors", as defined by
      Regulation D promulgated under the Securities Act.

	 	 	 	 
	 	 ix. 		
      It has the financial wherewithal and the capacity to
      perform its obligations hereunder and to manufacture and ship all orders
      of Finished Goods during the Term.

	 	 	 	 
	 	 x. 		
      Each Product, as well as pre-approved clips, marketing
      materials, photographs and samples thereof, and Biomatrix’s Marks and the
      uses herein in accordance with this Agreement, does not and will not
      violate any law, infringe on the rights of any person or entity or otherwise cause S2C to incur
liability to any third party including but not limited to infringement or
misappropriation of any copyright, patent, trademark, trade secret, or other
proprietary, property or other right. 

7

11.    
Indemnity 

(a)        
 Biomatrix shall defend, indemnify and hold S2C and its affiliates and each
of their employees, members, officers, directors, shareholders, contractors,
representatives and agents harmless from and against any and all liability,
loss, damage, expense, claim, or cause of action, including, without limitation,
reasonable legal fees and expenses (collectively, “Claims”), arising out of or
related to Biomatrix’s material breach of any of Biomatrix’s representations,
warranties or agreements contained herein. S2C shall promptly notify Biomatrix
in writing of any such claim and promptly tender the control of the defense and
settlement of any such claim to Biomatrix at Biomatrix’s expense; provided that
failure to give prompt notice will not relieve Biomatrix from its
indemnification obligation, except to the extent of liabilities that would have
been avoided had prompt notice been given. S2C will reasonably cooperate with
Biomatrix, at Biomatrix’s expense, in defending or settling such claim, provided
that Biomatrix may not settle any claim in a manner that adversely affects S2C’s
rights without S2C’s prior written consent. S2C may join in defense with counsel
of its choice at its own expense. 

(b)          S2C
shall defend, indemnify and hold Biomatrix and its affiliates and each of their
employees, officers, directors, shareholders, contractors, representatives and
agents harmless from any and all Claims arising out of or related to S2C’s
material breach of any of S2C’s representations, warranties or agreements
contained herein. Biomatrix shall promptly notify S2C in writing of any such
claim and promptly tender the control of the defense and settlement of any such
claim to S2C at S2C’s expense; provided that failure to give prompt notice will
not relieve S2C from its indemnification obligation, except to the extent of
liabilities that would have been avoided had prompt notice been given. Biomatrix
will reasonably cooperate with S2C, at S2C’s expense, in defending or settling
such claim, provided that S2C may not settle any claim in a manner that
adversely affects Biomatrix’s rights without Biomatrix’s prior written consent.
Biomatrix may join in defense with counsel of its choice at its own expense.

12.     Limitation of
Liability. Except for the obligations under above section 11, in
no event shall either party be responsible for any consequential, special or
punitive damages, including, without limitation, lost revenue or profits, in any
way arising out of or related to this Agreement, unless due to the gross
negligence or willful misconduct of the nonaffected party.

13.     Force
Majeure. Neither party shall have liability for any failure or
delay resulting from any governmental action, fire, flood, insurrection,
earthquake, power failure, riot, explosion, embargo, strikes whether legal or
illegal, labor or material shortage, transportation interruption of any kind,
work slowdown or any other condition that is not reasonably foreseeable and
beyond the control of either party affecting production or delivery in any
manner that such party is unable to overcome through the exercise of
commercially reasonable diligence (a “Force Majeure Event”). If any Force
Majeure Event occurs, the affected party will give prompt written notice to the
other party and will use commercially reasonable efforts to minimize the impact
of the event. Notwithstanding the foregoing, in the event the force majeure
event continues for more than 90 days, either party may terminate this
Agreement. 

14.    
Assignability. Neither party may assign its rights or
delegate its duties under this Agreement either in whole or in part without the
prior written consent of the other party, and any attempted assignment or
delegation without such consent will be void, provided, however, that either
party may assign its rights and obligations hereunder (i) to any affiliate or
controlled subsidiary, (ii) to any entity that is the survivor of a merger of
such party with or into such other entity, or (iii) to any acquiror of all or
substantially all of the stock or assets of such party.
Notwithstanding the foregoing, S2C may delegate the performance of certain
services to third parties (including without limitation fulfillment centers),
provided S2C remains responsible to Biomatrix for the delivery of such services
and (y) in the event of a Sale of Biomatrix during the first three (3) years of
this Agreement, this Agreement shall be assigned to the successor entity in such
Sale. This Agreement will bind and inure to the benefit of each party's
successors and permitted assigns. 

8

15.    
Confidentiality. Each party agrees and shall cause its
employees, if any, to agree to hold all Confidential Information (as hereinafter
defined) in trust and confidence and, except as may be authorized by the other
party in writing, shall not use any such Confidential Information for any
purpose other than as expressly set forth in this Agreement or disclose any
Confidential Information to any person, company or entity. As used herein,
“Confidential Information” shall mean any information relating to or disclosed
during the Term that is or should reasonably be understood to be confidential or
proprietary to either party, including, but not limited to, data and information
concerning the parties’ consumers and/or members, the material terms and
conditions of this Agreement, technical processes, source code, business plans,
projections, and marketing data. Notwithstanding the foregoing, information
shall not be deemed Confidential Information hereunder if such information: (i)
is known to the receiving party prior to receipt from the disclosing party
directly or indirectly from a source other than one having an obligation of
confidentiality to the disclosing party; (ii) becomes known (independently of
disclosure by the disclosing party) to the receiving party directly or
indirectly from a source other than one having an obligation of confidentiality
to the disclosing party; (iii) becomes publicly known or otherwise publicly
available, except through a breach of this Agreement by the receiving party; or
(iv) is independently developed by the receiving party by personnel without
access to the Confidential Information. The receiving party may disclose
Confidential Information pursuant to the requirements of applicable law, legal
process or government regulation, provided that it gives the disclosing party
reasonable prior written notice to permit the disclosing party to contest such
disclosure, and such disclosure is otherwise limited to the required disclosure.

16.    
Termination 

(a)     Termination For Cause.
Either party may terminate this Agreement if: (i) the other party breaches any
material term or condition of this Agreement and fails to cure such breach
within twenty-one (21) days after receipt of written notice of the same; (ii)
S2C fails to secure adequate funding to support a sales campaign, estimated to
be $250,000 dollars, or fails to sell $250,000 worth of products within the
1st 12 months of this agreement; (iii) the other party becomes the
subject of a voluntary petition in bankruptcy or any voluntary proceeding
relating to insolvency, receivership, liquidation, or composition for the
benefit of creditors; or (iv) the other party becomes the subject of an
involuntary petition in bankruptcy or any involuntary proceeding relating to
insolvency, receivership, liquidation, or composition for the benefit of
creditors, if such petition or proceeding is not dismissed within sixty (60)
days of filing. 

(b)     Effect of Termination. Upon
the effective date of the termination of this Agreement under Section 16(a)
above, S2C shall cease running any DR Advertisements and stop selling the
Products, subject to any existing contractual obligations for media buys and
sales related thereto. Within thirty (30) days of any termination or expiration
of this Agreement, each party will return all Confidential Information of the
other party in its possession and will not make or retain any copies of such
Confidential Information except as required to comply with any applicable legal
or accounting record keeping requirement. 

(c)     Survival. The following
provisions of this Agreement shall survive any expiration or termination hereof:
Sections 2, 3, 7, 8, 9 and 9 through 20, inclusive. 

9

17.   
 Publicity. Neither S2C nor Biomatrix shall
issue any public announcements regarding this Agreement or the relationship
created herein without the express written consent of the other party. 

18.     Dispute
Resolution. 

(a)         
Mandatory Procedures. The parties agree that any dispute arising out of
or relating to this Agreement shall be resolved solely by means of the
procedures set forth in this Section 20, and that such procedures constitute
legally binding obligations that are an essential provision of this Agreement.
If either party fails to observe the procedures of this Section, as may be
modified by their written agreement, the other party may bring an action for
specific performance of these procedures in any court of competent
jurisdiction.

(b)         
Equitable Remedies. Although the procedures specified in this Section 20
are the sole and exclusive procedures for the resolution of disputes arising out
of or relating to this Agreement, either party may seek a preliminary injunction
or other provisional equitable relief if, in its reasonable judgment, such
action is necessary to avoid irreparable harm to itself or to preserve its
rights under this Agreement. 

(c)         
Dispute Resolution Procedures. If a dispute between the parties cannot be
resolved by informal meetings and discussions within five days after
commencement thereof, the dispute shall be settled by binding arbitration, and a
corresponding judgment may be entered in a court of competent jurisdiction.
Arbitration of any dispute may be initiated by one party by sending a written
demand for arbitration to the other party. This demand will specify the matter
in dispute and request the appointment of an arbitration panel. The arbitration
panel will consist of one arbitrator named by S2C, one arbitrator named by
Biomatrix and a third arbitrator named by the two arbitrators so chosen. The
arbitration hearing will be conducted in accordance with the procedural rules
set forth in the JAMS/Endispute Streamlined Arbitration Rules & Procedures.
The site of the arbitration will be mutually determined by the parties.

19.    
Notices. All notices and approvals under this Agreement
shall be in writing and shall be given by courier or other personal delivery, by
nationally recognized overnight courier service, or by registered or certified
mail at the appropriate address indicated above or at a substitute address
designated by notice by the party concerned. Notices shall be deemed given (i)
when delivered, if sent by courier or personally delivered, (ii) on the business
day following the date sent, if sent by nationally recognized overnight courier
service, or (iii) five (5) days after mailing, if sent by first class registered
or certified mail, postage prepaid. 

20.    
Miscellaneous 

(a)         
Governing Law. This Agreement shall be governed by and construed in
accordance with the internal laws of the State of Arizona, without regard to
principles of conflicts of law.

(b)         
Severability. In the event that any provision of this Agreement is found
to be invalid, void or unenforceable, the remaining provisions shall remain
enforceable to the fullest extent permitted by law.

(c)        
 Relationship of Parties. S2C and Biomatrix are independent
contractors and this Agreement will not establish any relationship of
partnership, joint venture, employment, franchise or agency between S2C and
Biomatrix. Neither S2C nor Biomatrix will have the power to bind the other or
incur obligations on the other’s behalf without the other’s prior written
consent. 

(d)         
Entire Agreement. This Agreement, including all documents incorporated
herein by reference, constitutes the complete and exclusive agreement between
the parties with respect to the subject matter hereof, and supersedes and replaces any and all
prior or contemporaneous discussions, negotiations, understandings and
agreements, written and oral, regarding such subject matter. Any additional or
different terms in any purchase order or invoice by either party shall be deemed
objected to by the other party without need of further notice of objection, and
shall be of no effect or in any way binding upon the other party.

10

(e)         
Amendments; Waivers. This Agreement may be amended, and any provision
herein waived, only by a written document signed by authorized representatives
of the parties. The waiver of any breach or default of this Agreement will not
constitute a waiver of any subsequent breach or default, and will not act to
amend or negate the rights of the waiving party. 

(f)         
Counterparts. This Agreement may be executed in one or more counterparts,
each of which shall be deemed to be an original and both of which together shall
constitute one and the same instrument. 

IN WITNESS WHEREOF, the undersigned have executed and delivered
this Supply Agreement as of the date first written above. 

	 	SCIENCE 2 CONSUMERS, INC.
  
	 	 
	 	 
	 	By: 	/s/Edwon Lam 
	 	  	Edwon Lam, President 
	 	 	 
	 	 	 
	 	BIOMATRIX, INC. 
	 	 
	 	 
	 	By: 	/s/Burt Ensley 
	 		 Burt Ensley,
CEO  

11

EXHIBIT A 

INITIAL PRODUCTS 

Dermalastyl B Face Cream Jar 1oz. 

DermaLastyl Bx Pro Fromula 1.7 Oz 

Facial Scrub 1.7 oz 

Dermalastyl E-Eye serum Jar .5 oz 

Wrinkle Eye Radicator Tube .5 oz. 

Anti Wrinkle Aftershave 

12

EXHIBIT “B” 

EXCLUSIVE LICENSE AGREEMENT 

This Agreement (the “Agreement”) is made this 13th day of
October, 2015, by and between Biomatrix, Inc., an Arizona Corporation with its
principal place of business at PMB 1319, 2675 W. Hwy 89A Sedona, AZ 86336
(“BIOMATRIX”), and Protein Genomics, Inc., a Delaware corporation with its
principal place of business at PMB 1319, 2675 W Hwy 89A Sedona, AZ 86336
(“PGen”). 

RECITALS 

	A. 	
      BIOMATRIX has significant experience and expertise in the
      field of Direct To Consumer Sales, Marketing and distribution of Consumer
      Health Care Products.

	 	 
	B. 	
      PGen owns or has the exclusive right to market and sell
      certain consumer products, as more fully described in Exhibit A annexed
      hereto and made a part hereof (the “Initial Products” and, together with
      any New Products, as defined in Section 8 below, the
“Products”).

	 	 
	C. 	
      PGen desires that the Products be offered for sale by way
      of one or more Direct Response advertisements (the “DR Advertisements”)
      and other mutually agreed worldwide marketing and distribution channels,
      and BIOMATRIX desires to produce DR Advertisements and other marketing and
      sales distribution materials for, and sell, the Products, all on the terms
      and conditions set forth below.

	 	 
	D. 	
      BIOMATRIX shall not be limited to DTC marketing and has
      the right to market and sell the products in other markets and other sales
      channels.

NOW, THEREFORE, in consideration of the agreements contained
herein and for other good and valuable consideration, the receipt and
sufficiency of which are acknowledged by the parties, the parties hereby agree
as follows:

1.     BIOMATRIX’s
Obligations 

(a)        
 BIOMATRIX shall create DR Advertisements for the Products, in consultation
with PGen, which shall initially consist of DR print (“DR Print”)
advertisements, and shall thereafter include DR TV commercials (“DRTV”) and
other forms of DR Advertisements, following national rollout of BIOMATRIX’s DR
Print campaign for the Initial Products. The DRTV commercials may be of any
length determined by BIOMATRIX in its sole discretion.

(b)         
BIOMATRIX shall manage all creative, testing, media buying, telemarketing,
fulfillment and credit card processing relating to the sale of Products through
DR Advertisements. BIOMATRIX will work with PGen on appropriate publicity and
home shopping opportunities for the Products. If BIOMATRIX believes it
necessary, the parties will work together to adjust packaging of the Products.

(c)        
 BIOMATRIX may, but shall not be obligated to, present buying opportunities
online of the Products as part of its overall web strategy, including order
acceptance, billing and collection. 

13

2.     PGen’s
Obligations 

(a)          PGen
shall (1) supply finished goods inventory for the Products (“Finished Goods”);
(2) provide claims substantiation with respect to each Product (including
without limitation any relevant clinical data and support for claims in PGen’s
current print advertising); (3) provide assistance with securing testimonials
and cooperation from experts; and (4) arranging for reasonable appearances by
Burt Ensley to promote PGen-derived products in DR advertising, home shopping
and other channels of distribution; and (5) provide unlimited fully cleared
content required by BIOMATRIX to create DR Advertisements, including without
limitation all necessary rights to use names, likenesses, etc. (“Content”) (6)
All patent and IP are in good standing, and that PGen will aggressively defend
them against potential competition and infringement. BIOMATRIX shall pay PGen’s
(i) reasonable costs associated with clause (3) above and (ii) standard and
customary travel and meal expenses associated with clause (4) above, provided in
each case that individual expenses in excess of $100 must be preapproved in
writing by BIOMATRIX. Burt Ensley will not be required to make home shopping
appearances more than 12 times per year nor more than twice per month. Until
shipment of the Products, all inventory shall be owned by PGen; thereafter it
shall be owned by BIOMATRIX, subject to returns in accordance with Section 10
below. 

(b)          At no
additional cost to BIOMATRIX, PGen shall: 

Furnish to BIOMATRIX fully cleared and pre-approved clips
(video and audio), marketing materials, photographs and samples of the Products
for use in the DR Advertisements (the “PGen Cleared Materials”) and notify
BIOMATRIX in writing of any restrictions or limitations relating to the
advertising, distribution and sale thereof; and (c) All Products shall be
manufactured in accordance with industry standards, government approvals and
shall be fit for the purpose for which they are being created. 

3.     Orders;
Pricing 

(a)        
 Orders; Fulfillment. During the Term (as defined in Section 8
below), BIOMATRIX shall place orders for Products with PGen on a standard
purchase order that shall solely state the quantity of Products desired, the
purchase price therefore, the delivery dates requested, and the shipment
address. PGen shall respond in writing to all purchase orders that may be
submitted by BIOMATRIX to PGen confirming such order within five working days.
PGen agrees to accept any order placed by BIOMATRIX on such standard purchase
order and in accordance with the terms of this Agreement. All orders shall be
shipped DDP to such address or addresses as may be specified by BIOMATRIX in the
applicable purchase order. 

14

(b)         
Purchase Price.

	 	i. 	
      The initial purchase price for each Initial Product is
      set by mutual agreement. The purchase prices thereafter for each Product
      shall be equal to PGen’s mutually agreed upon costs for such Product
      (“Costs”).

	 	 	 
	 	ii. 	
      PGen shall invoice BIOMATRIX for the Products purchased
      by and delivered to BIOMATRIX or its designees, and BIOMATRIX will pay 1⁄2
      the invoice amount upon receipt by PGen of the Purchase Order, and, within
      45 days after the date any purchase order product is shipped, pay PGen the
      remaining 1⁄2 of the invoice amount for the Products so invoiced; provided,
      however, that any returns by BIOMATRIX to PGen in accordance with Section
      12 hereof shall be offset from the purchase price payable in respect of
      any purchase order and invoice in respect thereof.

(c)         
Pricing. 

The parties anticipate that the Initial Products will be
marketed in a three SKU sales unit consisting of a one-month supply of a
DermaLastyl-based system (e.g., (x) 1-oz. jar of DermaLastyl-B, (y) 1-month
supply of DermaLastyl-E, and (z) moisturizer) for the three SKUs (collectively,
a “Sales Unit”). BIOMATRIX intends to test multiple price points and offers with
respect to the Products, and does not presently know the retail price at which
it will end up selling the Sales Unit. BIOMATRIX also may, but shall not be
obligated to, explore trials, sampling and lead generation campaigns in an
effort to minimize customer acquisition cost and maximize customer lifetime
value. 

4.     Production &
Test Marketing 

(a)         
Commencing on the date of this Agreement BIOMATRIX will produce and begin
testing DR Advertisements for the Initial Products (the “Testing Period”).
During the Testing Period, BIOMATRIX will bear all of the costs of the test DR
advertising and will invest not less than $100,000 for the initial test DR
advertising, and additional sums if in BIOMATRIX’s good faith determination the
initial tests are successful.

(b)        
 BIOMATRIX will proceed with the National Roll-out if it achieves positive
results from its test DR advertising during the Testing Period. At the end of
the Testing Period, BIOMATRIX will assume financial and managerial
responsibility for public relations in connection with the Products. 

(c)          If
BIOMATRIX fails to roll out a national DR advertising campaign with respect to
the Initial Products by the end of the Testing Period, PGen shall have the right
to terminate this Agreement upon 30 days’ prior written notice with no further
liability to BIOMATRIX, provided, however, that any delay resulting from a
failure on the part of PGen to timely furnish all materials pursuant to Sections
2(a)(1), 2(a)(2) and (5) shall not trigger PGen’s rights under this Section
4(c).

(d)        
 Subsequent to successful testing, BIOMATRIX and PGen may work together to
modify packaging of the Products by mutual agreement.

(e)         
BIOMATRIX shall determine in its sole discretion whether to market the Products
individually or in any combination configuration (including continuity,
boxed-set, multi-pay and single-unit), provided that the price of each
individual SKU for a Product marketed in this manner is equal to the highest prevailing retail price for such Product and reflects
no discount, as indicated by the current product price chart reflected on the
attached Exhibit B (subject to future price reductions by PGen). 

15

5.     Exclusive Rights.
During the Term, BIOMATRIX shall have exclusive rights in the Territory (the
“Exclusive Rights”) to all Products in the following channels: (i) DR
television, (ii) home shopping, (iii) DR print, (iv) catalog, (v) Direct Mail,
(vi) DR radio, (vii) outbound telemarketing; (viii) online (including eCommerce,
lead generation and direct marketing) and (ix) retail. 

6.     No Right of First
Refusal on New Products. BIOMATRIX will not have rights on any new
cosmeceutical and dermaceutical product(s) (the “New Products”) created by PGen
during the Term. 

7.    
Territory. The Territory covered by this Agreement is
the People’s Republic of China and Europe. 

8.     Term.

The initial term of this Agreement (as such term may be renewed
pursuant to this Section 8(a), the “Term”) shall commence on the date of this
Agreement and shall continue for a period of 5 (5) years, provided that the
initial Term and any renewal Term shall automatically be renewed for additional
5 (5) year periods in the event that BIOMATRIX sells at least $500 Thousand of
Products per annum under the terms of this Agreement in the preceding 5-year
Term.

9.    
Ownership 

(a)        
 BIOMATRIX shall own the copyright in the DR Advertisements and all other
materials created by it or on its behalf hereunder. 

(b)          PGen
shall own any materials contained in the Products supplied to BIOMATRIX by PGen
and nothing in this Agreement shall confer in BIOMATRIX any right of ownership
in such materials. PGen grants to BIOMATRIX a exclusive, nonassignable (except
to affiliated entities), nontransferable, royalty-free license, in the United
States and for the Term, to the Products for use by BIOMATRIX in creating the DR
advertising in accordance with this Agreement. 

(c)        
 PGen’s trademarks, service marks, trade or company names, product and
service identifications, artwork and other symbols and devices associated with
the Products (“PGen’s Marks”) are and shall remain PGen’s property. PGen grants
to BIOMATRIX an exclusive, nonassignable, nontransferable, royalty-free license,
in the Territory and for the Term, to PGen’s Marks for use by (except to
affiliated entities) BIOMATRIX solely in accordance with this Agreement. All
uses by BIOMATRIX of PGen’s Marks shall insure solely to the benefit of PGen.

(d)         
BIOMATRIX’s trademarks, service markets, trade or company names, product and
service identifications, artwork and other symbols and devices associated with
the Products (“BIOMATRIX’s Marks”) are and shall remain BIOMATRIX’s
property.

10.    
Returns. PGen shall accept from BIOMATRIX returns of
units of Products and will credit BIOMATRIX for 100% of the purchase price paid
by BIOMATRIX to PGen for those units. 

11.    
Insurance. Each party shall obtain and maintain, at its
own expense, errors and omissions insurance covering the Products furnished by
PGen to BIOMATRIX hereunder, and the DR Advertisements and other advertising in
respect thereof, from a recognized and qualified insurance company in the amount
of at least One Million Dollars ($1,000,000) per occurrence and Three Million
Dollars ($3,000,000) all occurrences. Each such policy will
name the other party as an additional insured and shall be non-cancelable by a
party except after thirty (30) days prior written notice to such other party.
Each party will furnish to the other a certificate evidencing such policy as
soon as possible after the execution of this Agreement, but in no event later
than BIOMATRIX’s commencement of production of the first DRTV Commercial for a
Product. 

16

12.     Representations
and Warranties 

(a)         
BIOMATRIX represents and warrants that: 

	 	 	i. 	
      It has the right, authority and power to enter into and
      fully perform its obligations under this Agreement.

	 	 	 	 
	 	 	ii. 	
      To the best of BIOMATRIX’s knowledge, BIOMATRIX’s Marks
      or any use of them in accordance with this Agreement will not violate any
      law, infringe upon the rights of any person or entity, or other cause PGen
      to incur liability to any third party, including, but not limited to,
      infringement or misappropriation of any copyright, patent, trademark,
      trade secret, or other proprietary, property or other
  right.

(b)          PGen
represents and warrants that: 

	 	 	i. 	
      It has the right, authority and power to enter into and
      fully perform its obligations under this Agreement.

	 	 	 	 
	 	 	ii. 	
      It owns all right, title and interest in and to the
      Initial Products, and covenants that it will own all right, title and
      interest in and to all New Products, in each case free and clear of any
      liens or other encumbrances.

	 	 	 	 
	 	 	iii. 	
      It has the financial wherewithal and the capacity to
      perform its obligations hereunder and to manufacture and ship all orders
      of Finished Goods during the Term.

	 	 	 	 
	 	 	iv. 	
      Each Product, as well as pre-approved clips, marketing
      materials, photographs and samples thereof, and PGen’s Marks and the uses
      herein in accordance with this Agreement, does not and will not violate
      any law, infringe on the rights of any person or entity or otherwise cause
      BIOMATRIX to incur liability to any third party including but not limited
      to infringement or misappropriation of any copyright, patent, trademark,
      trade secret, or other proprietary, property or other
  right.

13.    
Indemnity 

(a)          PGen
shall defend, indemnify and hold BIOMATRIX and its affiliates and each of their
employees, members, officers, directors, shareholders, contractors,
representatives and agents harmless from and against any and all liability,
loss, damage, expense, claim, or cause of action, including, without limitation,
reasonable legal fees and expenses (collectively, “Claims”), arising out of or
related to PGen’s material breach of any of PGen’s representations, warranties
or agreements contained herein. BIOMATRIX shall promptly notify PGen in writing
of any such claim and promptly tender the control of the defense and settlement
of any such claim to PGen at PGen’s expense; provided that failure to give
prompt notice will not relieve PGen from its indemnification obligation, except
to the extent of liabilities that would have been avoided had prompt notice been given.
BIOMATRIX will reasonably cooperate with PGen, at PGen’s expense, in defending
or settling such claim, provided that PGen may not settle any claim in a manner
that adversely affects BIOMATRIX’s rights without BIOMATRIX’s prior written
consent. BIOMATRIX may join in defense with counsel of its choice at its own
expense. 

17

(b)         
BIOMATRIX shall defend, indemnify and hold PGen and its affiliates and each of
their employees, officers, directors, shareholders, contractors, representatives
and agents harmless from any and all Claims arising out of or related to
BIOMATRIX’s material breach of any of BIOMATRIX’s representations, warranties or
agreements contained herein. PGen shall promptly notify BIOMATRIX in writing of
any such claim and promptly tender the control of the defense and settlement of
any such claim to BIOMATRIX at BIOMATRIX’s expense; provided that failure to
give prompt notice will not relieve BIOMATRIX from its indemnification
obligation, except to the extent of liabilities that would have been avoided had
prompt notice been given. PGen will reasonably cooperate with BIOMATRIX, at
BIOMATRIX’s expense, in defending or settling such claim, provided that
BIOMATRIX may not settle any claim in a manner that adversely affects PGen’s
rights without PGen’s prior written consent. PGen may join in defense with
counsel of its choice at its own expense. 

14.     Limitation of
Liability. Except for the obligations under paragraph 13, in no
event shall either party be responsible for any consequential, special or
punitive damages, including, without limitation, lost revenue or profits, in any
way arising out of or related to this Agreement, unless due to the gross
negligence or willful misconduct of the nonaffected party.

15.     Force
Majeure. Neither party shall have liability for any failure or
delay resulting from any governmental action, fire, flood, insurrection,
earthquake, power failure, riot, explosion, embargo, strikes whether legal or
illegal, labor or material shortage, transportation interruption of any kind,
work slowdown or any other condition that is not reasonably foreseeable and
beyond the control of either party affecting production or delivery in any
manner that such party is unable to overcome through the exercise of
commercially reasonable diligence (a “Force Majeure Event”). If any Force
Majeure Event occurs, the affected party will give prompt written notice to the
other party and will use commercially reasonable efforts to minimize the impact
of the event. Notwithstanding the foregoing, in the event the force majeure
event continues for more than 90 days, either party may terminate this
Agreement. 

16.    
Assignability. Neither party may assign its rights or
delegate its duties under this Agreement either in whole or in part without the
prior written consent of the other party, and any attempted assignment or
delegation without such consent will be void, provided, however, that either
party may assign its rights and obligations hereunder (i) to any affiliate or
controlled subsidiary, (ii) to any entity that is the survivor of a merger of
such party with or into such other entity, or (iii) to any acquiror of all or
substantially all of the stock or assets of such party. Notwithstanding the
foregoing, BIOMATRIX may delegate the performance of certain services to third
parties (including without limitation fulfillment centers), provided BIOMATRIX
remains responsible to PGen for the delivery of such services and (y) in the
event of a Sale of PGen during the first three (3) years of this Agreement, this
Agreement shall be assigned to the successor entity in such Sale. This Agreement
will bind and inure to the benefit of each party's successors and permitted
assigns. 

17.    
Confidentiality. Each party agrees and shall cause its
employees, if any, to agree to hold all Confidential Information (as hereinafter
defined) in trust and confidence and, except as may be authorized by the other
party in writing, shall not use any such Confidential Information for any
purpose other than as expressly set forth in this Agreement or disclose any
Confidential Information to any person, company or entity. As used herein,
“Confidential Information” shall mean any information relating to or disclosed
during the Term that is or should reasonably be understood to be confidential or
proprietary to either party, including, but not limited to, data and information
concerning the parties’ consumers and/or members, the material terms and conditions of this Agreement,
technical processes, source code, business plans, projections, and marketing
data. Notwithstanding the foregoing, information shall not be deemed
Confidential Information hereunder if such information: (i) is known to the
receiving party prior to receipt from the disclosing party directly or
indirectly from a source other than one having an obligation of confidentiality
to the disclosing party; (ii) becomes known (independently of disclosure by the
disclosing party) to the receiving party directly or indirectly from a source
other than one having an obligation of confidentiality to the disclosing party;
(iii) becomes publicly known or otherwise publicly available, except through a
breach of this Agreement by the receiving party; or (iv) is independently
developed by the receiving party by personnel without access to the Confidential
Information. The receiving party may disclose Confidential Information pursuant
to the requirements of applicable law, legal process or government regulation,
provided that it gives the disclosing party reasonable prior written notice to
permit the disclosing party to contest such disclosure, and such disclosure is
otherwise limited to the required disclosure. 

18

18.   
 Termination 

(a)          Termination
For Cause. Either party may terminate this Agreement if: (i) the other party
breaches any material term or condition of this Agreement and fails to cure such
breach within twenty-one (21) days after receipt of written notice of the same;
(ii) the other party becomes the subject of a voluntary petition in bankruptcy
or any voluntary proceeding relating to insolvency, receivership, liquidation,
or composition for the benefit of creditors; or (iii) the other party becomes
the subject of an involuntary petition in bankruptcy or any involuntary
proceeding relating to insolvency, receivership, liquidation, or composition for
the benefit of creditors, if such petition or proceeding is not dismissed within
sixty (60) days of filing. 

(b)        
 Effect of Termination. Upon the effective date of the termination
of this Agreement under Section 18(a) above, BIOMATRIX shall cease running any
DR Advertisements and stop selling the Products, subject to any existing
contractual obligations for media buys and sales related thereto. Within thirty
(30) days of any termination or expiration of this Agreement, each party will
return all Confidential Information of the other party in its possession and
will not make or retain any copies of such Confidential Information except as
required to comply with any applicable legal or accounting record keeping
requirement. 

(c)         
Survival. The following provisions of this Agreement shall survive any
expiration or termination hereof: Sections 2, 3, 7, 8, 9 and 9 through 22,
inclusive. 

19.    
Publicity. Neither BIOMATRIX nor PGen shall issue any
public announcements regarding this Agreement or the relationship created herein
without the express written consent of the other party. 

20.     Dispute
Resolution. 

(a)         
Mandatory Procedures. The parties agree that any dispute arising out of
or relating to this Agreement shall be resolved solely by means of the
procedures set forth in this Section 20, and that such procedures constitute
legally binding obligations that are an essential provision of this Agreement.
If either party fails to observe the procedures of this Section, as may be
modified by their written agreement, the other party may bring an action for
specific performance of these procedures in any court of competent
jurisdiction.

(b)         
Equitable Remedies. Although the procedures specified in this Section 20
are the sole and exclusive procedures for the resolution of disputes arising out
of or relating to this Agreement, either party may seek a preliminary injunction or other provisional
equitable relief if, in its reasonable judgment, such action is necessary to
avoid irreparable harm to itself or to preserve its rights under this
Agreement. 

19

(c)         
Dispute Resolution Procedures. If a dispute between the parties cannot be
resolved by informal meetings and discussions within five days after
commencement thereof, the dispute shall be settled by binding arbitration, and a
corresponding judgment may be entered in a court of competent jurisdiction.
Arbitration of any dispute may be initiated by one party by sending a written
demand for arbitration to the other party. This demand will specify the matter
in dispute and request the appointment of an arbitration panel. The arbitration
panel will consist of one arbitrator named by BIOMATRIX, one arbitrator named by
PGen and a third arbitrator named by the two arbitrators so chosen. The
arbitration hearing will be conducted in accordance with the procedural rules
set forth in the JAMS/Endispute Streamlined Arbitration Rules & Procedures.
The site of the arbitration will be in 20. 

21.   
 Notices. All notices and approvals under
this Agreement shall be in writing and shall be given by courier or other
personal delivery, by nationally recognized overnight courier service, or by
registered or certified mail at the appropriate address indicated above or at a
substitute address designated by notice by the party concerned. Notices shall be
deemed given (i) when delivered, if sent by courier or personally delivered,
(ii) on the business day following the date sent, if sent by nationally
recognized overnight courier service, or (iii) five (5) days after mailing, if
sent by first class registered or certified mail, postage prepaid. 

22.    
Miscellaneous 

(a)        
 Governing Law. This Agreement shall be governed by and construed in
accordance with the internal laws of the State of Arizona, without regard to
principles of conflicts of law.

(b)        
 Severability. In the event that any provision of this Agreement is
found to be invalid, void or unenforceable, the remaining provisions shall
remain enforceable to the fullest extent permitted by law.

(c)         
Relationship of Parties. BIOMATRIX and PGen are independent contractors
and this Agreement will not establish any relationship of partnership, joint
venture, employment, franchise or agency between BIOMATRIX and PGen. Neither
BIOMATRIX nor PGen will have the power to bind the other or incur obligations on
the other’s behalf without the other’s prior written consent. 

(d)        
 Entire Agreement. This Agreement, including all documents
incorporated herein by reference, constitutes the complete and exclusive
agreement between the parties with respect to the subject matter hereof, and
supersedes and replaces any and all prior or contemporaneous discussions,
negotiations, understandings and agreements, written and oral, regarding such
subject matter. Any additional or different terms in any purchase order or
invoice by either party shall be deemed objected to by the other party without
need of further notice of objection, and shall be of no effect or in any way
binding upon the other party.

(e)         
Amendments; Waivers. This Agreement may be amended, and any provision
herein waived, only by a written document signed by authorized representatives
of the parties. The waiver of any breach or default of this Agreement will not
constitute a waiver of any subsequent breach or default, and will not act to
amend or negate the rights of the waiving party. 

(f)         
Counterparts. This Agreement may be executed in one or more counterparts,
each of which shall be deemed to be an original and both of which together shall
constitute one and the same instrument. 

20

IN WITNESS WHEREOF, the undersigned have executed and delivered
this Supply Agreement as of the date first written above. 

	 	Biomatrix, Inc. 
	 	 
	 	 
	 	By: 	/s/Burt Ensley  
	 	                     
      Burt Ensley, President  
	 	 
	 	 
	 	PGEN, INC. 
	 	 
	 	 
	 	By: 	/s/Burt Ensley  
	 	                    
      Burt Ensley, CEO  

21

EXHIBIT A 

INITIAL PRODUCTS 

Dermalastyl B Face Cream Jar 1oz. 

DermaLastyl Bx Pro Fromula 1.7 Oz 

Facial Scrub 1.7 oz 

Dermalastyl E-Eye serum Jar .5 oz 

Wrinkle Eye Radicator Tube .5 oz. 

Anti Wrinkle Aftershave 

22

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}]]